Stanley Abel
Directeur/Bestuurslid bij ADYNXX, INC.
Actieve functies van Stanley Abel
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ADYNXX, INC. | Directeur/Bestuurslid | 01-01-2008 | - |
Independent Dir/Board Member | - | - | |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | Voorzitter | 23-03-2021 | - |
Directeur/Bestuurslid | 01-02-2014 | 23-03-2021 | |
Algemeen Directeur | 01-02-2014 | 23-03-2021 | |
President | 01-02-2014 | 23-03-2021 | |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | Voorzitter | - | - |
President | - | - | |
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | Directeur/Bestuurslid | - | - |
Algemeen Directeur | 01-04-2022 | - | |
President | 01-04-2022 | - |
Loopbaan van Stanley Abel
Eerdere bekende functies van Stanley Abel
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Corthera, Inc.
Corthera, Inc. Pharmaceuticals: MajorHealth Technology Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA. | Algemeen Directeur | 01-10-2007 | 01-02-2010 |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Financieel Directeur/CFO | 01-01-2007 | 01-01-2007 |
Oprichter | 01-01-2007 | 01-01-2007 | |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Financieel Directeur/CFO | 01-01-2003 | 01-05-2005 |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Voorzitter | 14-09-2017 | - |
Adynxx, Inc. (Old)
Adynxx, Inc. (Old) Pharmaceuticals: MajorHealth Technology Adynxx, Inc. develops clinical-stage pharmaceutical addressing pain at its molecular roots. Its technology platform provides treating the development of pain following surgery or trauma and established chronic pain syndrome. The company was founded by Julien Mamet in October 2007 and is headquartered in San Francisco, CA. | Directeur/Bestuurslid | 01-01-2008 | - |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░ ░░░░░ ░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Opleiding van Stanley Abel
The University of Chicago | Masters Business Admin |
Indiana University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 14 |
Operationeel
Director/Board Member | 4 |
Chief Executive Officer | 3 |
Chairman | 3 |
Sectoraal
Health Technology | 8 |
Commercial Services | 5 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
ADYNXX, INC. | Health Technology |
Bedrijven in privébezit | 9 |
---|---|
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Commercial Services |
Corthera, Inc.
Corthera, Inc. Pharmaceuticals: MajorHealth Technology Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA. | Health Technology |
Sonexa Therapeutics, Inc.
Sonexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sonexa Therapeutics, Inc. developed drug treatments for Alzheimer's disease (AD) and related disorders. Its lead compound, ST101 had demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. The company was founded in January 2008 and was headquartered in San Diego, CA. | Health Technology |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
Adynxx, Inc. (Old)
Adynxx, Inc. (Old) Pharmaceuticals: MajorHealth Technology Adynxx, Inc. develops clinical-stage pharmaceutical addressing pain at its molecular roots. Its technology platform provides treating the development of pain following surgery or trauma and established chronic pain syndrome. The company was founded by Julien Mamet in October 2007 and is headquartered in San Francisco, CA. | Health Technology |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | Commercial Services |
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | Commercial Services |
- Beurs
- Insiders
- Stanley Abel
- Ervaring